Ardelyx (Ardelyx) ROCE % : -33.55% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ardelyx's annualized ROCE % for the quarter that ended in Mar. 2024 was -33.55%.

Ardelyx ROCE % Historical Data

The historical data trend for Ardelyx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx ROCE % Chart

Ardelyx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-44.11

-43.44

-113.72

-56.08

-30.48

Ardelyx Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-71.15	-39.75	17.92	-41.64	-33.55

Ardelyx ROCE % Calculation

Ardelyx's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-56.646	/	( ( (190.066 - 65.603)	+	(297.579 - 50.393) )	/ 2 )
	=	-56.646	/	( (124.463	+	247.186)	/ 2 )
	=	-56.646	/	185.8245
	=	-30.48 %

Ardelyx's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-89.356	/	( ( (297.579 - 50.393)	+	(342.382 - 56.895) )	/ 2 )
	=	-89.356	/	( ( 247.186	+	285.487 )	/ 2 )
	=	-89.356	/	266.3365
	=	-33.55 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Ardelyx (NAS:ARDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ardelyx ROCE % Related Terms

Thank you for viewing the detailed overview of Ardelyx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx (Ardelyx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ARDX:Mexico 41X:Germany 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Executives

David P. Rosenbaum	officer: Chief Development Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Justin A Renz	officer: Chief Financial Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer	officer: See Remarks	78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks	officer: See Remarks	C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
Laura A Williams	officer: Chief Medical Officer	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Robert Ora Felsch	officer: See Remarks	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Michael Raab	director, officer: President & CEO	1119 ST PAUL STREET, BALTIMORE MD 21202
Susan Rodriguez	officer: Chief Commercial Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Jeffrey W Jacobs	officer: VP, Chemistry	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli	officer: See Remarks	C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010